Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
17.86
-0.43 (-2.32%)
At close: Jul 24, 2026, 4:00 PM EDT
17.75
-0.11 (-0.59%)
After-hours: Jul 24, 2026, 7:22 PM EDT
Quince Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Quince Therapeutics stock has a consensus rating of "Buy" and an average price target of $83.33. The average 1-year stock price forecast is 366.70% higher than the current stock price, while the lowest is $70 (+292.05%) and the highest is $100 (+460.07%).
Price Target: $83.33 (+366.70%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Quince Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 1 | 0 | 0 | 3 | 3 |
| Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 4 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 3 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Initiates $100 | Buy | Initiates | $100 | +460.07% | Jun 29, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $80 | Buy | Initiates | $80 | +348.05% | Jun 24, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $80 | Buy | Initiates | $80 | +348.05% | Jun 23, 2026 |
| Maxim Group | Maxim Group | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Feb 2, 2026 |
| Lucid Capital | Lucid Capital | Sell Downgrades n/a | Sell | Downgrades | n/a | n/a | Jan 30, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
12.79M
EPS This Year
-2.00
from -336.00
EPS Next Year
-6.60
from -2.00
EPS and Forward PE are based on non-GAAP adjusted numbers.